ATH

Alterity Therapeutics

Pharmaceuticals, Biotechnology & Life Sciences

Alterity Therapeutics Limited focuses on developing therapies to treat neurodegenerative diseases associated with aging, like Alzheimer's and Parkinson's disease. The company leverages a novel drug development platform aimed at targeting misfolded proteins. Positioned as a pioneer in this field, Alterity aims to address significant unmet needs in the neurosciences market.

biotechnology

neurodegenerative diseases

therapeutic development

pharmaceuticals

Shorted

short percentage0.19%

reported shorts20.3M

shares on issue10.875B

About

website

alteritytherapeutics.com

industry

Pharmaceuticals, Biotechnology & Life Sciences

address

Level 3, 62 Lygon Street, CARLTON, VIC, AUSTRALIA, 3053

Connect

Key Metrics

market cap

$87.00M

price$0.01

employees

More Pharmaceuticals, Biotechnology & Life Sciences Stocks

Other shorted stocks in this sector

View all stocks in this industry

Short Position Trends

Track bearish sentiment and short interest over time

Historical Price Data

View stock price movements, volume, and trading patterns

Industry & Focus

biotechnology

neurodegenerative diseases

therapeutic development

pharmaceuticals

aged care

Company Overview

AI-generated company summary

Company History

Alterity Therapeutics Limited, originally known as Prana Biotechnology, was founded in 1997 in Melbourne, Australia. It initially went public on the ASX in 2000, focusing on therapeutic solutions for neurodegenerative diseases. A pivotal moment arrived in 2019 when the company rebranded to Alterity Therapeutics to reflect its broadened focus. Key milestones include the strategic advancement of its leading drug compounds, ATH434, into clinical trials.

Competitive Advantages

Alterity Therapeutics holds a competitive edge through its proprietary drug development platform that targets misfolded proteins, a significant factor in neurodegenerative diseases. Its strategic focus on developing first-in-class treatments positions it uniquely within a market that has few effective therapeutic options.

Risk Factors

•Regulatory challenges in drug approval processes
•High R&D costs with uncertain return on investment
•Competitive pressure from larger pharmaceutical companies

Recent Developments

Last 6 months

Recently, Alterity has advanced its lead candidate ATH434 into Phase 2 clinical trials, with promising early data suggesting potential efficacy in treating Multiple System Atrophy, a form of Parkinsonian disorder.

Key People

Leadership team at Alterity Therapeutics

David Stamler

CEO

Dr. David Stamler has extensive experience in the pharmaceutical industry, having held leadership positions in research and development. He joined Alterity as Chief Executive Officer bringing a wealth of clinical and regulatory expertise.

Rene Sindlev

CFO

Rene Sindlev is the Chief Financial Officer at Alterity Therapeutics, with a background in accounting and financial management in the biotechnology sector.